Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study

References

• CongdonNVingerlingJRKleinBEPrevalence of cataract and pseudophakia/aphakia among adults in the United StatesArch Ophthalmol2004122448749415078665
   PubMedGoogle Scholar
• Facts about cataract Available from: http://www.nei.nih.gov/health/cataract/cataract_facts.aspAccessed September 21, 2011
   Google Scholar
• KelkarAKelkarJAmuakuWKelkarUShaikhAHow to prevent endophthalmitis in cataract surgeries?Indian J Ophthalmol200856540340718711270
   PubMed Web of Science ®Google Scholar
• MinassianDCRosenPDartJKExtracapsular cataract extraction compared with small incision surgery by phacoemulsification: a randomised trialBr J Ophthalmol200185782282911423457
   PubMed Web of Science ®Google Scholar
• AabergTMJrFlynnHWJrSchiffmanJNewtonJNosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomesOphthalmology19981056100410109627649
   PubMed Web of Science ®Google Scholar
• JacobsDJLengTFlynnHWJrShiWMillerDGeddeSJDelayed-onset bleb-associated endophthalmitis: presentation and outcome by culture resultClin Ophthalmol2011573974421691583
   PubMedGoogle Scholar
• NovosadBDCalleganMCSevere bacterial endophthalmitis: towards improving clinical outcomesExpert Rev Ophthalmol20105568969821572565
   PubMedGoogle Scholar
• SpeakerMGMilchFAShahMKEisnerWKreiswirthBNRole of external bacterial flora in the pathogenesis of acute postoperative endophthalmitisOphthalmology19919856396492062496
   PubMed Web of Science ®Google Scholar
• BannermanTLRhodenDLMcAllisterSKMillerJMWilsonLAThe source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresisArch Ophthalmol199711533573619076208
   PubMedGoogle Scholar
• NagakiYHayasakaSKadoiCBacterial endophthalmitis after small-incision cataract surgery. Effect of incision placement and intraocular lens typeJ Cataract Refract Surg2003291202612551662
   PubMed Web of Science ®Google Scholar
• MasketMChangDFLaneDFCataract in the adult eye: preferred practice patternSan Francisco, CAAmerican Academy of Ophthalmology2006 Available from: http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=a80a87ce-9042-4677-85d7-4b876deed276Accessed February 27, 2012
   Google Scholar
• BarryPSealDVGettinbyGLeesFPetersonMRevieCWESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a European multicenter studyJ Cataract Refract Surg200632340741016631047
   PubMed Web of Science ®Google Scholar
• JensenMKFiscellaRGMoshirfarMMooneyBThird- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 yearsJ Cataract Refract Surg20083491460146718721704
   PubMed Web of Science ®Google Scholar
• ChangDFBraga-MeleRMamalisNProphylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member surveyJ Cataract Refract Surg200733101801180517889779
   PubMed Web of Science ®Google Scholar
• OlsonRDonnenfeldEBucciFAJrMethicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgeryClin Ophthalmol201041505151421191448
   PubMedGoogle Scholar
• HaasWPillarCMTorresMMorrisTWSahmDFMonitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance studyAm J Ophthalmol20111524567574e56321652021
   PubMed Web of Science ®Google Scholar
• DeramoVALaiJCFastenbergDMUdellIJAcute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacinAm J Ophthalmol2006142572172516989762
   PubMed Web of Science ®Google Scholar
• KarpeckiPDepaolisMHunterJABesifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyClin Ther200931351452619393842
   PubMed Web of Science ®Google Scholar
• TepedinoMEHellerWHUsnerDWPhase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisCurr Med Res Opin20092551159116919323612
   PubMed Web of Science ®Google Scholar
• McDonaldMBProtzkoEEBrunnerLSEfficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisOphthalmology2009116916151623e161119643483
   PubMed Web of Science ®Google Scholar
• ComstockTLPaternoMRDecoryHHUsnerDWSafety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studiesClin Drug Investig20103010675685
   Web of Science ®Google Scholar
• SilversteinBEAllaireCBatemanKMGearingerLSMorrisTWComstockTLEfficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childrenClin Ther2011331132621397770
   PubMed Web of Science ®Google Scholar
• CambauEMatratSPanXSTarget specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coliJ Antimicrob Chemother200963344345019147516
   PubMed Web of Science ®Google Scholar
• Besivance^® package insertRochester, NYBausch and Lomb Inc2009
   Google Scholar
• HaasWPillarCMZurenkoGELeeJCBrunnerLSMorrisTWBesifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteriaAntimicrob Agents Chemother20095383552356019506065
   PubMed Web of Science ®Google Scholar
• Final report on the safety assessment of Carbomers-934, -910, -934P, -940, -941, and -962Int J Toxicol198212109141
   Google Scholar
• SeeNARussellJConnorsKABassPAdsorption of inorganic and organic ions to polycarbophil as a means of sustained-release dosage formulationPharm Res1987432442473509289
   PubMed Web of Science ®Google Scholar
• LehrCMLeeYHLeeVHImproved ocular penetration of gentamicin by mucoadhesive polymer polycarbophil in the pigmented rabbitInvest Ophthalmol Vis Sci1994356280928148188475
   PubMed Web of Science ®Google Scholar
• BowmanLMSiEPangJArchibaldRFriedlaenderMDevelopment of a topical polymeric mucoadhesive ocular delivery system for azithromycinJ Ocul Pharmacol Ther200925213313919284320
   PubMed Web of Science ®Google Scholar
• AbelsonMProtzkoEShapiroAGarces-SoldanaABowmanLA randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitisClin Ophthalmol20071217718219668507
   PubMedGoogle Scholar
• NessPJMamalisNWernerLAn anterior chamber toxicity study evaluating Besivance, AzaSite, and CiprofloxacinAm J Ophthalmol20101504498504e49120678751
   PubMed Web of Science ®Google Scholar
• MillerDFlynnPMScottIUAlfonsoECFlynnHWJrIn vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolatesArch Ophthalmol2006124447948316606872
   PubMedGoogle Scholar
• HaasWPillarCMHesjeCKSanfilippoCMMorrisTWBactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzaeJ Antimicrob Chemother20106571441144720435780
   PubMed Web of Science ®Google Scholar
• HaasWGearingerLSUsnerDWDecoryHHMorrisTWIntegrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profileClin Ophthalmol201151369137922034556
   PubMedGoogle Scholar
• HaasWPillarCMMorrisTWSahmDMAntibiotic resistance trends in ocular pathogens – An update from the ARMOR 2009 and ARMOR 2010 surveillance studiesPaper presented at the Association for Research in Vision and Ophthalmology annual meetingMay 1–5, 2011Ft Lauderdale, FL
   Google Scholar
• AdebayoAParikhJGMcCormickSAShifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear InfirmaryGraefes Arch Clin Exp Ophthalmol2011249111111920532549
   PubMed Web of Science ®Google Scholar
• FreidlinJAcharyaNLietmanTMCevallosVWhitcherJPMargolisTPSpectrum of eye disease caused by methicillin-resistant Staphylococcus aureusAm J Ophthalmol2007144231331517659970
   PubMed Web of Science ®Google Scholar
• BlomquistPHMethicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis)Trans Am Ophthalmol Soc200610432234517471350
   PubMedGoogle Scholar
• GoecksTWernerLMamalisNToxicity comparison of intraocular azithromycin with and without a bioadhesive delivery system in rabbit eyesJ Cataract Refract Surg20123813714522078120
   PubMed Web of Science ®Google Scholar
• KreznerKLZhangJZCoffeyMJSafety of repeated topical ocular administration of a polycarbophil-based formulation (DuraSite®) in several models of ocular surgery in rabbitsJ Cataract Refract Surg201238469670422440439
   PubMed Web of Science ®Google Scholar